2027 Global IP and Trade Summit
January 27 to 29, 2027
Location
Ft. Myers, Florida, United States
Contact
Registration
Save the date! January 27-29, 2027!
Global commerce is reshaping how intellectual property is created, enforced, and valued. Join us for an essential deep dive into the complex intersection of trade, IP, privacy, export controls, and anti-counterfeiting—topics often overlooked in professional forums.
This essential program brings together international practitioners, government agencies, and academic experts to explore how trade regulations and privacy laws intersect with IP strategy, creating both challenges and opportunities. Learn how tariffs, export restrictions, and evolving trade agreements can transform enforcement strategies overnight, while cross-border data regulations and counterfeit markets challenge traditional protections.
Whether you're in-house counsel managing cross-border portfolios or outside counsel advising multinational clients, you'll gain actionable insights to turn trade-related risks into strategic advantages. Walk away equipped to navigate this evolving landscape with confidence and adapt your legal strategies to the realities of today's global marketplace.
Venue: Marriott Sanibel Harbour Resort
Room Rate: $289 per night plus $15 Resort Fee and applicable taxes.
Please note at time of reservation, Resort Fee will appear as $35 but will be discounted upon check-in. Self-parking is $25 per day, but is also waived so will be handled onsite at check-in.
Reservation cut-off date - TUESDAY, January 5, 2027. The Group Rate and Resort Fee and Parking Discounts will not be available after that date, so be sure to book your rooms early!
Reservations can be made by calling 1-800-767-777 or by using the following RESERVATION LINK
NOTE: AIPLA does NOT engage any third party vendors to assist with room reservations. All room reservations should be made directly using the Reservation link above, or by contacting the hotel directly.
Sponsorship & exhibitor opportunities information coming soon.
News
-
AIPLA Comments on the Copyright Office's Proposed Fee Schedule Adjustment
May 8, 2026
Arlington, VA. May 1, 2026 – The American Intellectual Property Law Association (AIPLA) submitted comments in response to the U.S. Copyright Office’s Notice of Proposed Rulemaking on adjustments to its fee schedule. -
AIPLA Submits Comments on the Enlarged Board of Appeal’s 11 Preliminary Opinion in G 1/25
May 1, 2026
Arlington, VA. April 17, 2026 – The American Intellectual Property Law Association (AIPLA) submitted comments on the Enlarged Board of Appeal’s 11 March 2026 preliminary opinion in G 1/25, addressing whether patent descriptions must be adapted following claim amendments. -
AIPLA Files Amicus Brief in Range of Motion Products, LLC v. Armaid Company Inc.
April 20, 2026
Arlington, VA — April 17, 2026 — The American Intellectual Property Law Association (AIPLA) filed an amicus curiae brief with the U.S. Court of Appeals for the Federal Circuit in Range of Motion Products, LLC v. Armaid Company Inc., No. 23-2427, supporting rehearing and rehearing en banc. AIPLA urges the Court to restore clarity to design patent law by (1) reaffirming that Gorham v. White (1871) provides the sole governing test for infringement and forecloses any separate “plainly dissimilar” threshold, and (2) confirming that claim construction may not be used to exclude any visual portions of the overall claimed design. -
AIPLA Comments on CNIPA Draft Measures for Prioritized Patent Examination
April 1, 2026
Arlington, VA. March 30, 2026 – The American Intellectual Property Law Association (AIPLA) submitted comments to the China National Intellectual Property Administration (CNIPA) regarding the Draft Measures for the Administration of Prioritized Examination of Patents. -
AIPLA Files Amicus Brief in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc
March 31, 2026
Arlington, VA. March 27, 2026 – The American Intellectual Property Law Association (AIPLA) filed an amicus curiae brief with the Supreme Court in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889. AIPLA urges the Court to affirm the Federal Circuit’s application of the established Iqbal/Twombly pleading standard and inducement law in reviewing Hikma’s motion to dismiss Amarin’s claim that Hikma’s conduct, in combination with its “skinny label,” induced infringement of Amarin’s patented treatment methods.